Verzenio plus Faslodex improved progression-free survival in HR+/HER2– advanced breast cancer after CDK/6i failure, with a ...

The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...

Proof-of-mechanism has been established for TNG260 based on pharmacodynamic data from on-treatment patient biopsies, with favorable safety, tolerability and pharmacokinetic profiles shown at the ...

Interim data has shown benefits of the camizestrant combo over standard treatment in ESR1-mutant breast cancer.

AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli ...

No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine ...

Eli Lilly and Company's latest 10-K report for the year ended December 31, 2024, reveals significant financial growth. The company reported a revenue of $45,042.7 million, marking a 32% increase from ...

As with other drugs, Verzenio (abemaciclib) can cause side effects, such as abdominal pain, nausea and vomiting, and fatigue. If you are not able to tolerate the side effects of Verzenio ...

The non-incretin portfolio also grew by 20%, with notable contributions from Verzenio and Jaypirca. International markets, including Europe, Japan, and China, showed robust growth, with Mounjaro ...

Both figures fell short of expectations on Wall Street but reflect a forecast Lilly made last month. Revenue from the breast cancer treatment Verzenio also helped in the fourth quarter, climbing 36% ...